Linezolid-related toxicities are prominent and have been a cause for concern in the three-drug BPaL regimen for highly drug-resistant TB, which combines Johnson & Johnson’s Sirturo (bedaquiline) ), the TB Alliance’s pretomanid and Pfizer Inc..’s Zyvox (linezolid).
In an interview with Scrip, Mel Spigelman, president and CEO of the TB Alliance, outlined some of the key aspects...







